

---

## Agenda Item G.1

### Report on material decisions of the Regulatory and Professional Policy Committee

---

From: Katherine Morrow, Chair of the Regulatory and Professional Policy Committee

The Regulatory and Professional Policy Committee met on Thursday, 16 February 2023, at 10am. The meeting was held in hybrid format, in PSI House and online via MS Teams.

The agenda items below refer to the matters before Council for decision.

The full agenda for the Committee meeting can be found in Annex 1, and this highlights the additional items discussed and items for information only.

#### Agenda Item E – Approval of Committee Workplan 2023

The Committee discussed the draft workplan that sets out the key strategic projects from the PSI Service Plan 2023 that will be overseen by the Regulatory and Professional Policy Committee, in addition to the core and ongoing work falling under the remit of the Committee.

The Committee noted the considerable indicative schedule of work to be carried out in 2023 and discussed project outputs and milestones in terms of their feasibility, timelines and competing priorities.

The Committee is recommending its 2023 Workplan to Council for approval.

#### Agenda Item G – Update to PSI Training Information for Vaccinations and Emergency Medicines in Response to NIAC changes on the Management of Anaphylaxis, following Vaccination

The Committee was asked to consider an update to PSI training information for vaccinations and emergency medicines.

The Committee was provided with an update on draft changes to the PSI Training Algorithm, which are proposed following a number of queries from pharmacists and other stakeholders seeking clarification on what training would be required to safely administer adrenaline (epinephrine) in emergency circumstances in the community setting and the appropriate administration of adrenaline in circumstances of anaphylaxis other than following administration of a vaccine.

Committee discussed the draft changes, highlighting the importance of pharmacists using their professional judgement. Committee recommended that the information contained in the update be highlighted on the PSI website and in the next PSI newsletter to registrants.

The Committee is recommending that the proposed changes to the PSI Training Algorithm be approved by Council.

## Agenda Item H – Schools of Pharmacy annual reports 2021/22

The Committee was asked to consider an annual report from each of the three Schools of Pharmacy for the 2021/22 academic year.

The Committee discussed the annual reports including their purpose in relation to the accreditation process. Committee sought clarification on the schools' fitness to practise processes and PSI's role in relation to this. Committee heard that the schools' fitness to practise processes are a requirement of PSI accreditation standards, which include the requirement to update PSI as part of the annual reporting process, and that PSI's role is to ensure there are appropriate systems in place.

Committee heard that a communication was sent in January 2023 to all registered pharmacies and pharmacists highlighting a number of considerations around the appropriate supervision of experiential learning placements and pharmacy students' role and responsibilities while on pharmacy placement.

The Committee is recommending that the annual reports received from each of the three Schools of Pharmacy for the 2021/22 academic year are accepted.

## Agenda Item J.3 –Third Country Qualification Recognition route: Recommendations for approval to the adaptation period training placements criteria

The Committee were asked to consider two proposed amendments to the PSI adaptation period training placements criteria.

The first proposed amendment is to allow for a tutor pharmacist at an approved adaptation period training establishment to be permitted to supervise more than one (up to three maximum) adaptation period trainees and/or APPEL students, at the same time, in certain circumstances and subject to the approval of the PSI.

The second amendment is to allow applicants to undertake a part-time adaptation period, subject to the approval of the PSI and where the total duration of part-time training still equals the overall adaptation period duration the trainee has been advised they must complete. Such requests would be considered by PSI on a case-by-case basis and subject to the approval of the PSI.

The Committee is recommending the two proposed amendments to the PSI adaptation period training placements criteria to Council for approval.

## Annex 1



**Agenda for PSI Regulatory and Professional Policy Committee  
held on 16 February 2023 at 10am.**

**The meeting will be in hybrid format held at PSI House and on Microsoft Teams.**

**Colour code: Red—for decision; Green—for discussion; Blue—for information**

Agenda Notation: \* - document provided in advance; \*\* - will be presented in slide deck at meeting;  
\*\*\* - verbal update

Indicative time	Item and descriptor		Presenter
10.00	A	Apologies	Chair
10.02	B	Declaration of Interests (See appendix A below)	Chair
10.05	C	Approval of Meeting Agenda*	Chair
10.10	D	Approval of Minutes - 1 December 2022 meeting*	Chair
10.15	E	Approval of Committee Workplan 2023*	Chair
10.25	F	2023 Workforce Project – Assess emerging risks to the continued availability of a professional pharmacy workforce within community and hospital pharmacy	Grant Thornton
	F.1	Update on project progress – literature review, survey analysis and focus group meetings**	
11.40	G	Update to PSI Training Information for Vaccinations and Emergency Medicines in Response to NIAC changes on the Management of Anaphylaxis, following Vaccination*	P Corbett
11.50	H	Annual Reports 2022 – Schools of Pharmacy*	A Mellett
11.55	I	Quarterly update on IOP operations and developments*	A Mellett
12.00	J	Third Country Qualification Recognition Route	J Bryan
	J.1	Update on project progress - Operationalisation of Third Country Qualification Recognition Route*	
	J.2	Project Health Card update*	

	J.3	<b>TCQR: Recommendations for approval to the adaptation period training placements criteria*</b>	
12.20	K	<b>Approval of Mystery Shopper Exercise Report*</b>	É Crimmins
12.40	L	<b>Draft guidelines on delineation in RPBs***</b>	J Bryan
12.50	M	<b>Report on ongoing work on COVID-19 response**</b>	D Burns
13.00	N	<b>2023 Work Plan Projects – Project Health Card updates</b>	
	N.1	<b>Review the CPD Model for pharmacists*</b>	A Mellett
	N.2	<b>Develop a CPD model for pharmaceutical assistants*</b>	A Mellett
	N.3	<b>Community Pharmacy - Standards Based Regulatory Model*</b>	J Bryan
	N.4	<b>Advance Reform of the Pharmacy Act*</b>	O Carroll
	N.5	<b>Development of a Patient Experience Programme*</b>	O Carroll
	N.6	<b>Stakeholder Engagement with DoH and HSE on Sláintecare implementation and pharmacy integration*</b>	O Carroll
13.15	O	<b>Proposed meeting dates for remainder of 2023:</b> <ul style="list-style-type: none"> <li>• Thursday, 13 April</li> <li>• Thursday 8 June</li> <li>• Thursday 21 September</li> <li>• Thursday 30 November</li> </ul> <b>AOB close of meeting</b>	Chair

***We anticipate the meeting should end at approximately: 13.20pm  
Katherine Morrow, Chair of the Regulatory and Professional Policy Committee***

## APPENDIX A

### **Pharmacy Act 2007 Schedule 1, Section 9: Disclosure of certain interests**

9. (1) In this paragraph— “connected relative”, in relation to a person, means a spouse, a man and woman who are not married to each other but are cohabiting as husband and wife, parent, brother, sister, child or spouse of a child of the person;

“meeting” means a meeting of the Council or of a committee of the Council;

“member” includes a member of a committee of the Council;

“specified matter” means—

- (a) an arrangement to which the Council is a party or a proposed such arrangement, or
- (b) a contract or other agreement with the Council or a proposed such contract or agreement.

(2) A member present at a meeting where a specified matter arises who, otherwise than in his or her capacity as a member, has an interest in that matter—

- (a) shall at the meeting, disclose that fact and the extent of the interest,
- (b) may not influence or seek to influence a decision to be made in relation to the matter,
- (c) shall absent himself or herself from the meeting or that part of the meeting during which the matter is being discussed,
- (d) may not vote on a decision relating to the matter, and
- (e) may not take part in any further deliberation of the Council or any of its committees relating to the matter.

(3) For the purposes of this paragraph, but without prejudice to the generality of *subparagraph (2)*, a member shall be regarded as having an interest in a matter if a connected relative of that member or a nominee of either of them has such an interest.

(4) The disclosure shall be recorded in the minutes of the meeting and, for as long as the specified matter is being dealt with by the meeting, the member making the disclosure may not be counted for the purposes of determining the presence of a quorum for the meeting.

(5) The question of whether a member’s course of conduct, is or would be a contravention of *subparagraph (2)* shall be determined by the chair, whose decision shall be final, and the particulars of the determination shall be recorded in the minutes of the meeting.

(6) Where the member referred to in *subparagraph (4)* is the chair, the meeting shall choose another member to chair it for the purposes of the determination.

(7) If satisfied that a member has contravened *subparagraph (2)*, the Minister may remove the member from office and that person is then disqualified from office.